Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 response-guided combination therapy study in treatment-naive HBeAg-positive chronic hepatitis B with normal ALT
2019-004978-26Phase 2Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tomligisiran, cetrelimab, tenofovir disoproxil fumarate, tenofovir alafenamide and peginterferon alfa-2a in Chronic Hepatitis B (CHB) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: HBsAg seroclearance after treatment discontinuation. Status: unknown.
02
Drugs
tomligisirancetrelimabtenofovir disoproxil fumaratetenofovir alafenamidepeginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2019-004978-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004978-26.